(ONC) BeOne Medicines Ltd. Business Model Canvas Research

BeOne Medicines Ltd. relies on local commercialization partners to win oncology access country by country, since reimbursement, tendering, and hospital logistics still depend on local execution. Its regional network helps push products across the U.S., Europe, China, and other markets while lowering launch friction and speeding payer access.

• Local partners handle reimbursement
• They support distribution and logistics
• They improve country-level market access

Diagnostic and biomarker collaborators are core to BeOne Medicines Ltd.’s precision-oncology model because they help match eligible patients to therapies using tumor and blood testing. In 2024, BeOne Medicines reported $3.8 billion in revenue, and its BTK and PD-1 portfolios need biomarker-linked patient finding to lift use in targeted and immuno-oncology care.

• Find eligible patients faster
• Support biomarker-backed use
• Lift adoption in oncology

BeOne Medicines Ltd. must make oncology drugs under GMP rules, with release testing, lot-to-lot consistency, and supply checks built into every batch. This keeps product quality steady and supports uninterrupted treatment for patients and providers across global markets.

• Release testing before shipment
• Batch consistency across sites
• Supply assurance for global access

BeOne Medicines builds sales, medical affairs, and reimbursement teams in priority markets to turn trial results into hospital use and formulary wins. Its commercial engine already shows scale: BRUKINSA topped $2 billion in annual sales in 2024, proving specialty oncology access can convert clinical data into real product revenue.

• Builds hospital and payer access
• Supports formulary and reimbursement wins
• Turns data into oncology revenue

BeOne Medicines Ltd. moved its headquarters to Basel, Switzerland, in 2025, anchoring the company in a top biopharma hub and supporting a more global operating model. Basel sits in Switzerland, which ranked 1st in the 2025 Global Innovation Index, so the location also strengthens access to talent, partners, and regulators.

• HQ moved to Basel in 2025
• Supports global operating structure
• Places BeOne in a biopharma hub

BeOne Medicines Ltd. operates in more than 45 countries across six continents, and that footprint is a key commercial and regulatory asset. It lets the company run faster global launches, build local market access, and spread execution risk across a wider base; in 2025, its geographic reach also supported $2.0 billion+ in revenue scale.

• 45+ countries
• Six-continent operating base
• Speeds international launches
• Supports local regulatory access

Brukinsa is an oral BTK inhibitor and Tevimbra is a PD-1 antibody, so BeOne Medicines can cover two major cancer pathways with one targeted drug and one immuno-oncology drug. Brukinsa drove about $2.6B in 2024 sales, showing strong scale, while Tevimbra adds a second growth engine across solid tumors and blood cancers.

• Two distinct mechanisms
• Targets different cancer pathways
• Competes in two therapy classes

BeOne Medicines Ltd. pairs internal R&D with in-licensed assets, so it is not dependent on one innovation stream. In 2025, that mix supports a broader pipeline across oncology and raises the odds of future approvals, while the company keeps a global commercial base in more than 45 markets.

• Internal R&D plus external alliances
• Broader shot at approvals
• More partnership optionality

Patient support services help BeOne Medicines Ltd. address the access and adherence frictions that often hit specialty oncology, where real-world oral therapy nonadherence can run around 20% to 30%. By guiding patients through treatment navigation, reimbursement, and follow-up, BeOne can improve continuity of use and keep patients on therapy longer.

• Supports access and reimbursement help
• Improves adherence in specialty oncology
• Strengthens real-world treatment continuity

BeOne Medicines Ltd uses post-market safety monitoring to track safety, usage, and outcomes for its global oncology products after launch. With BRUKINSA and TEVIMBRA already sold in many markets in 2025, ongoing pharmacovigilance supports label maintenance, faster issue detection, and long-term trust with regulators and clinicians.

• Tracks adverse events after launch
• Supports global label maintenance
• Protects trust in oncology use

Scientific meetings and congresses remain a core HCP channel for BeOne Medicines Ltd., because major oncology events like ASCO draw 40,000+ attendees and shape treatment practice. Digital HCP portals then keep product, safety, and trial updates live between meetings, helping clinicians make faster evidence-based adoption decisions.

• Congresses build peer-to-peer oncology education.
• Portals extend data after the event ends.
• Together they support evidence-based uptake.

Payer and formulary access teams are a key oncology channel for BeOne Medicines Ltd. They work with payers and health systems to win coverage, since reimbursement often decides how fast patients can start treatment.

In oncology, access teams can be as important as sales: without formulary approval, even strong products stall. One line: coverage first, uptake second.

• Secure payer coverage
• Shape formulary access
• Speed patient reach

Tevimbra reaches solid-tumor patients across approved uses, and that matters because solid tumors make up about 90% of adult cancers worldwide. This segment moves BeOne Medicines Ltd. beyond hematology and widens its addressable market, with lung, gastric, and esophageal cancers driving much of the need.

• About 90% of adult cancers are solid tumors
• Broadens BeOne beyond hematology
• Expands Tevimbra’s market reach

Payers and health systems decide whether BeOne Medicines Ltd. treatments get broad oncology access, so coverage hinges on clear clinical value and budget impact data. In oncology, even a strong efficacy result can stall without health-technology evidence, outcomes data, and pricing that fits public and private formularies.

• Coverage drives patient access
• Proof must beat budget impact
• Needs HEOR and real-world data

BeOne Medicines Ltd. faces recurring regulatory and pharmacovigilance costs because each new approval adds local filings, safety tracking, and label updates across markets. In 2024, the Company reported $3.8 billion in revenue, while global safety and compliance work stayed tied to every new country and indication.

• More approvals, more reporting, more label upkeep
• Safety monitoring is ongoing, not one-time
• Costs scale with each market and indication

External partnerships can bring upfront fees, milestones, and royalties, and BeOne Medicines Ltd. uses alliances to widen its pipeline while lowering discovery risk. That trade-off adds contract costs on top of heavy R&D spend; in 2024, BeOne Medicines Ltd. reported about $3.8 billion in revenue and about $2.0 billion in R&D expense.

• Upfront fees fund access.
• Milestones raise total deal cost.
• Royalties cut future margins.
• Alliances spread pipeline risk.

BeOne Medicines Ltd. earns collaboration and licensing revenue from external alliances that bring upfront fees, milestones, and shared commercialization income, adding non-product cash to its mix of in-house and in-licensed assets. In 2025, the company’s reported revenue base stayed product-led, with collaboration income still a useful second stream that can reduce reliance on a single drug.

• Fees from partner deals
• Shared commercialization income
• Adds non-product revenue

Partnered programs can add milestone cash as BeOne Medicines Ltd. advances assets, and licensed or co-developed drugs can also generate royalties. This stream can lift earnings beyond direct sales, especially while core oncology products scale.

• Milestones follow progress.
• Royalties come from partners.
• Upside can outlast launch cycles.